Sign Out
Non-selective monoamine oxidase (MAO) inhibitors are contraindicated for use with Levodopa + Carbidopa (Twindopa). These inhibitors must be discontinued at least two weeks before starting Levodopa + Carbidopa (Twindopa). Levodopa + Carbidopa (Twindopa) may be administered concomitantly with the manufacturer's recommended dose of an MAO inhibitor with selectivity for MAO type B (e.g. selegiline hydrochloride). (See Interactions.)
Levodopa + Carbidopa (Twindopa) is contraindicated in patients with narrow-angle glaucoma and in patients with known hypersensitivity to any component of this medication. Since levodopa may activate a malignant melanoma, it should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.
Use in patients with severe psychoses.
See also Use in Pregnancy & Lactation.
Continue with Google